Clincosm LogoSign in Get a demo

t2d

Showing 1 - 8 of 8
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

T2D Trial

Not yet recruiting
  • T2D
    • (no location specified)
    Jul 31, 2023

    PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, T2D Trial in Nantong (control group: lifestyle intervention+ metformin+

    Enrolling by invitation
    • PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
    • T2D
    • control group: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone
    • the experimental group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar
    • Nantong, Jiangsu, China
      Gu Yunjuan
    Feb 27, 2023

    Type 2 Diabetes, T2D Trial in Worldwide (LY3209590, Insulin Glargine)

    Recruiting
    • Type 2 Diabetes
    • T2D
    • Birmingham, Alabama
    • +71 more
    Jan 26, 2023

    Overweight, Obesity, Chronic Kidney Disease Trial in Worldwide (Tirzepatide, Placebo)

    Not yet recruiting
    • Overweight
    • +4 more
    • Northridge, California
    • +25 more
    Sep 9, 2022

    Type2 Diabetes, Diabetes, Diabetes, Type 2 Trial in Worldwide (Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo)

    Recruiting
    • Type2 Diabetes
    • +7 more
    • Tirzepatide Dose 1
    • +2 more
    • Birmingham, Alabama
    • +55 more
    Aug 8, 2022

    Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes

    Active, not recruiting
    • IGT - Impaired Glucose Tolerance
    • T2D
    • Oral Glucose Tolerance Test
    • +3 more
    • New Haven, Connecticut
      Yale University
    Feb 8, 2022

    T2D Trial in Copenhagen (Cross-over study)

    Completed
    • T2D
    • Cross-over study
    • Copenhagen, Denmark
      Department of Exercise, Nutrition and Sports, Faculty of Science
    Nov 24, 2020

    T2D Trial in Shanghai (Peanut, Control)

    Completed
    • T2D
    • Peanut
    • Control
    • Shanghai, China
      Liang Sun
    Feb 27, 2019